NOVEL GLUCOSE DERIVATIVE AS SGLT-2 INHIBITOR
The present invention relates to a novel glucose derivative, and said novel compound is useful as an SGLT-2 inhibitor. In addition, the novel glucose derivative according to the present invention has a relatively higher melting point, lo...

WO/2018/132073A1

A β-PEPTIDO SUGAR-COPOLYMER
There is provided a β-peptido sugar-copolymer having the structure of formula (I) as defined herein, or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, or a salt thereof, or a mixture of the same. There is provided a proce...

METHOD FOR PREPARING OLIGOMERIC MANNURONIC DIACID
A novel method for preparing an important bioactive substance, oligomeric mannuronic diacid. The method uses oligomeric mannuronic acid as the starting material and obtains the target substance by means of steps of acid degradation and a...

SUGAR-DIPEPTIDE CONJUGATES AS FLAVOR MOLECULES
The present invention relates to compounds and compositions for use in enhancing flavor and umami taste of food products. Particularly, the present invention relates to compounds of the general formula I) and compositions comprising them.

WO/2016/120250A1

SUGAR-DIPEPTIDE CONJUGATES AS FLAVOR MOLECULES
The present invention relates to compounds and compositions for use in enhancing flavor and umami taste of food products. Particularly, the present invention relates to compounds of the general formula (I) and compositions comprising them.

OXIDATION OF URONIC ACIDS TO ALDARIC ACIDS
Disclosed is the oxidation of uronic acids, such as galacturonic acid, to the corresponding aldaric acids, such as galactaric acid, under neutral or acidic conditions. Use is made of a supported gold catalyst. The oxidation occurs in goo...

WO/2016/041470A1

SGLT-2 INHIBITORS
Provided are compounds of SGLT-2 inhibitors, pharmaceutically acceptable salts, hydrides and stereoisomers thereof. The compounds are employed in pharmaceutical compositions, and methods of making and use, including treating a person in ...

PROTECTING GROUPS FOR "Z NUCLEOTIDE" AND METHODS THEREOF
The present disclosure provides a unique methodology and protecting groups that enable synthesis of oligonucleotides having Z nucleotide in an easy, clean and site-specific fashion with high yield. In particular, the method causes little...

WO/2015/191303A2

PROTECTING GROUPS FOR "Z NUCLEOTIDE" AND METHODS THEREOF
The present disclosure provides a unique methodology and protecting groups that enable synthesis of oligonucleotides having Z nucleotide in an easy, clean and site-specific fashion with high yield. In particular, the method causes little...

PROCESS FOR THE PREPARATION OF EMPAGLIFLOZIN
An improved process for the preparation of empagliflozin is disclosed. Novel intermediates of formulas (13) and (14) for the preparation of empagliflozin are also disclosed, wherein R1 and R2 are independently hydrogen or hydroxyl protec...

PROCESS FOR THE PURIFICATION OF DAPAGLIFLOZIN
The present invention provides a process for the preparation of (1C)-2,3,4,6-tetra- O-acetyl-1,5-anhydro-1-[4-chloro-3-(4-ethoxybenzyl)phenyl]-D
-glucitol of Formula III. The invention also provides a process for the purification of dapa...

GLYCOSIDASE INHIBITORS AND USES THEREOF
The invention provides compounds for inhibiting glycosidases, prodrugs of the compounds, and pharmaceutical compositions including the compounds or prodrugs of the compounds. The invention also provides methods of treating diseases and d...

CATALYTIC OXIDATION OF URONIC ACIDS TO ALDARIC ACIDS
Disclosed is the oxidation of uronic acids, such as galacturonic acid, to the corresponding aldaric acids (characterized by the formula HOOC-(CHOH)n-COOH, with n being an integer of from 1 to 5) such as galactaric acids. The starting mat...

NOVEL GLYCOSIDE COMPOUNDS
Compounds of formula (I) as shown in the disclosure, in which X, Y, and Z are defined herein. Also disclosed are pharmaceutical compositions and therapeutical methods related to these compounds.